SUGGESTED READING
Bartlett NL: Modern treatment of Hodgkin lymphoma. Curr Opin Hematol 15:408–414, 2008.
Campbell BA, Voss N, Pickles T, et al: Involved-nodal radiation therapy as a component of combination therapy for limited–stage Hodgkin’s lymphoma: A question of field size. J Clin Oncol 26:5170-5174, 2008.
Chetaille B, Bertucci F, Finetti P, et al: Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113:2765–3775, 2009.
Cozen W, Hamilton AS, Zhao P, et al: A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma. Blood 114:4014-4020, 2009.
De Bruin ML, Sparidans J, van’t Veer MB, et al: Breast cancer risk in female survivors of Hodgkin’s lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol 27:4239-4246, 2009.
Eich HT, Diehl V, Görgen H, et al: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199-4206, 2010.
Eichenauer DA, Bredenfeld H, Haverkamp H, et al: Hodgkin's lymphoma in adolescents treated with adult protocols: A report from the German Hodgkin study group. J Clin Oncol 27:6079–6085, 2009.
Eichenauer DA, Engert A, Dreyling M, et al: Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 22 (suppl 6):vi55-vi58, 2011.
Encisco-Mora V, Broderick P, Ma Y, et al: A genome-wide association study of Hodgkin’s lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21, and 10p14 (GATA3). Nat Genet 42:1126-1130, 2010.
Engert A, Diehl V, Franklin J, et al: Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548–4554, 2009.
Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640-652, 2010.
Goodman KA, Riedel E, Serrano V, et al: Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol 26:5240–5247, 2008.
Herbst C, Engert A: Meta-analyses of early-stage Hodgkin lymphoma. Acta Haematol 125:32-38, 2011.
Herbst C, Rehan FA, Brillant C, et al: Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: A systematic review. Haematologica 95:494-500, 2010.
Hoppe RT, Hira Advani R, Ambinder RF, et al: NCCN physician guidelines: Hodgkin Lymphoma 2011. Available at: www.nccn.org.
Klimm B, Franklin J, Stein H, et al: Lymphocyte-depleted classical Hodgkin’s lymphoma: A comprehensive analysis from the German Hodgkin study group. J Clin Oncol 29:3914-3920, 2011.
Kobe C, Dietlein M, Franklin J, et al: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989–3994, 2008.
Ma Y, Visser L, Roelofsen H, et al: Proteomics analysis of Hodgkin lymphoma: Identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 111:2339–2346, 2008.
Moskowitz C, Sweetenham J: The role of hematopoietic stem cell transplantation in hodgkin lymphoma. Cancer Treat Res 144:1–16, 2009.
Moskowitz CH, Yahalom J, Zelenetz AD, et al: High-dose chemo-radiotherapy for relapsed or refractory hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol, 148:890–897, 2010.
Ng A, Constine LS, Advani R, et al: ACR Appropriateness Criteria: Follow-up of Hodgkin’s lymphoma. Curr Probl Cancer 34:211-227, 2010.
Paumier A, Ghalibafian M, Beaudre A, et al: Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Phys 80:199-205, 2011.
Sarina B, Castagna L, Farina L, et al: Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: A retrospective study based on the time of HLA typing and donor availability. Blood 115:3671–3677, 2010.
Yahalom J: Role of radiation therapy in Hodgkin's lymphoma. Cancer J 15:155–160, 2009.
Abbreviations in this chapter
CALGB = Cancer and Leukemia Group B; ECOG = Eastern Cooperative Oncology Group; EORTC = European Organisation for Research and Treatment of Cancer; GELA = Groupe d'Etude des Lymphomes de l'Adulte; GHSG = German Hodgkin's Study Group; MSKCC = Memorial Sloan-Kettering Cancer Center; NCCN = National Comprehensive Cancer Network; NCIC = National Cancer Institute of Canada; SEER = Surveillance, Epidemiology and End Results; SWOG = Southwest Oncology Group; WHO = World Health Organization
